SmartLabs is proud to announce that CEO Brian Taylor has been honored by the PharmaVoice 100 as one of the top leaders in life sciences industry. With over 20 years of experience, Taylor has been instrumental in driving innovation since joining SmartLabs in 2020. Now, as CEO, he continues to steer the company toward strategic growth while advancing its mission to enable groundbreaking scientific discoveries.

Pilot Program Now Underway in Collaboration with Life Sciences Real Estate Leader 

In this discussion with Rebecca Willumson, Seth Taylor, Co-Founder and Chief Business Officer at SmartLabs, delves into the current landscape of the venture capital market, fully automated manufacturing, and highlights key opportunities shaping the future of biotechnology. Explore his valuable perspectives.

Discover how HI-Bio utilized SmartLabs' lab programs and operational services to support their research and development efforts in precision medicines for immune-mediated diseases. The SmarLabs’ model kept pace with the company’s growth including in-licensing opportunities for diverse therapeutics so the team could focus on what matters most, their science.

Learn how Mitsubishi, a Japanese based pharmaceutical company, expanded globally to accelerate their research efforts for neurological diseases. In their search for top-tier research space in Boston, SmartLabs played a crucial role, offering pharmaceutical-grade infrastructure and assisting the team in navigating U.S. regulations critical to their success in a new market.

Discover Xsphera Biosciences: leaders and pioneers in transforming cancer research with their novel ex vivo tumor tissue platform. With a 90-95% failure rate in oncology therapeutics entering clinical trials, they're changing the game. Their innovative platform predicts patient responses with precision. In revolutionizing drug development, they're driving a shift in cancer treatment and increasing success rates

Financing will be used to further develop and optimize SmartLabs innovative product portfolio in order to address the modern needs of customers across the life sciences industry.

Taylor to oversee the development and provision of scientific service offerings for SmartLabs' partners engaged in programs of various sizes and scales, from early discovery to commercial manufacturing.

Embark on a captivating journey where SmartLabs revolutionizes Cue Biopharma's drug development, breaking boundaries and transforming lives—Discover the limitless possibilities and the future of medicine powered by SmartLabs, and prepare to be inspired—Read more.

Explore how SmartLabs accelerated Sana Biotechnology's rapid launch of innovative R&D programs, providing advanced resources and unwavering support for exponential growth—Read more to witness their dynamic partnership and groundbreaking advancements in biotechnology.

Entrada Therapeutics accelerates its R&D and achieves significant growth by leveraging SmartLabs' flexible infrastructure, customized labs, and wraparound services, enabling them to rapidly advance research, attract top talent, and secure substantial funding. Read more about their success story here.

Discover how SmartLabs empowers Scorpion Therapeutics, an emerging biotech startup in oncology, through high-quality support, rapid access to top-notch infrastructure, and a collaborative partnership, fueling groundbreaking research and driving remarkable strides in cancer treatment—Read more.